About ZemairaWhat is Alpha-1?Patient SupportAlpha-1 Guardian ProgramSpecialty Pharmacy PartnersCSL Behring AssuranceReimbursement ResourcesZemaira Plant TourMy Steps for Healthy LivingWalk For Breath CelebrationPatient SupportFor Healthcare ProfessionalsPrescribing InformationImportant Safety InformationAlready Treating Your Alpha-1?Newly diagnosed with alpha-1?Diagnosed with Chronic Lung Disease?Receive Zemaira at no charge for up to 2 weeks.

Reimbursement Resources

As part of our continuing commitment to our patient communities, we are pleased to offer assistance with insurance-related questions and support for qualified patients who are uninsured or underinsured, or who cannot afford their prescribed therapy.

Skilled representatives who are highly experienced in issues pertaining to insurance reimbursement can assist you by:

  • Providing guidance when your insurance company has denied coverage
  • Supplying therapy codes for insurance and medical forms
  • Reporting trends in coverage and reimbursement
  • Explaining new federal and state policies and how they may impact you
  • Providing literature searches (medical and clinical) to support a particular choice of therapy

These professionals have an impressive track record of successfully assisting providers, patients, and third-party payers for over 10 years. To speak with a representative, call the Reimbursement Answerline at 1-800-676-4266 Monday through Friday from 8 a.m. to 5 p.m. ET.

Our online Reimbursement Resource Center is designed to provide helpful insights for understanding medical service costs and related insurance matters, including health insurance reimbursement for Zemaira®. Through the Reimbursement Resource Center, you can obtain information about:

Insurance Payers and Plans—Presents details about health insurance companies and the plans they offer.

Insurance Coverage Trends—Provides information on what coverage payers are offering for outpatient and inpatient care.

Universal Billing codes and HCPCS and CPT codes—Outlines billing codes and other codes you may need.

Reimbursement Alerts—Contains summaries of current changes in health insurance reimbursement for plasma therapies and other relevant issues.

Important Safety Information

Alpha1-Proteinase Inhibitor (Human), Zemaira is indicated for chronic augmentation and maintenance therapy for adults with alpha1-proteinase inhibitor (A1-PI) deficiency and emphysema. Clinical data demonstrating the long-term effects of chronic augmentation therapy with Zemaira are not available.

Zemaira may not be appropriate for the following adult individuals as they may experience severe reactions, including anaphylaxis: individuals with a known hypersensitivity and/or history of anaphylaxis or severe systemic reaction to A1-PI products or their components, and individuals with selective IgA deficiencies who have known antibodies against IgA.

In clinical studies, the following treatment-related adverse reactions were reported in 1% of subjects: asthenia (fatigue), injection-site pain, dizziness, headache, paresthesia (tingling), and pruritus (itching).

Zemaira is derived from human plasma. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

Please see full prescribing information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.